Scientists have unveiled a groundbreaking method to compel individual cells to systematically dismantle and dispose of unwanted proteins. This cutting-edge "Targeted Protein Degradation" technology, initially hailed for its therapeutic potential, is now attracting an entirely different kind of attention: from corporate boards. Industry insiders are already calling it the most significant HR innovation since the invention of the anonymous severance package, openly fantasizing about its applications.
Dr. Meredith Thorne, head of "Strategic Human Capital Reconfiguration" at OmniCorp Solutions, hailed the development as a "paradigm shift in talent management." In a leaked internal memo obtained by Hambry, Thorne elaborated, "For far too long, we've relied on archaic methods like 'performance reviews' or 'constructive dismissal' to manage... shall we say, less-than-optimal human resources. This breakthrough promises a surgical approach to disengagement, allowing us to proactively degrade elements that no longer align with our synergistic growth objectives. Imagine an era where problematic 'proteins' simply cease to exist within the corporate organism, leaving behind a perfectly optimized, lean, and compliant structure."
Initial inquiries from Fortune 500 companies reportedly focus on applying the cellular "disposal system" to a wide array of perceived "organizational friction points," "legacy talent," and "brand narrative inconsistencies." Sources close to the discussions suggest the ultimate goal is to "cleanse the corporate ecosystem" of anything slowing down quarterly earnings. This includes, but is not limited to, anyone raising inconvenient questions about executive bonuses, advocating for unionization, challenging dubious climate claims, or daring to ask "why" too many times in a meeting. The focus is on swift, silent, and untraceable removal.
The move comes as companies grapple with increasing scrutiny over "quiet quitting" and "employee retention" statistics, offering what one anonymous C-suite executive called "the ultimate solution to ghosting your own workforce, without the messy paper trail." While ethical concerns have been raised by precisely zero of the venture capitalists Hambry contacted — and only a handful of junior bioethicists who were quickly dismissed — the potential for "silent, systemic removal" is reportedly generating significant buzz in investor circles, particularly those specializing in "disruption management."
Sources confirm initial proof-of-concept trials will focus on degrading "the protein of collective bargaining" in critical supply chain logistics divisions, followed by "the gene of environmental activism" within resource extraction sectors.
